ADMA Biologics, Inc. — Fiscal 2014 Form 10-K Summary
Business context and reporting period
The filing covers the fiscal year ended December 31, 2014. ADMA is a late-stage biopharmaceutical company developing plasma-derived biologics for immune-compromised patients. Its lead candidate, RI-002, is an RSV-antibody-enriched intravenous immune globulin intended initially for primary immunodeficiency disease. The company also operates ADMA BioCenters, a source-plasma collection business in Georgia.
ADMA reported positive Phase III results for RI-002 in December 2014. The single-arm trial enrolled 59 patients at nine U.S. centers, with no reported serious bacterial infections during the trial. The company had not generated revenue from RI-002 therapeutics; substantially all reported revenue came from plasma sales and related licensing activities.
Financial performance and key metrics
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Total revenue | $5.916 million | $3.068 million | +92.8% |
| Product revenue | $5.840 million | $3.024 million | +93.1% |
| License revenue | $0.076 million | $0.044 million | +71.4% |
| Gross profit | $2.173 million | $1.044 million | +108.1% |
| Gross margin | 36.7% | 34.0% | +2.7 percentage points |
| Operating loss | $16.019 million | $15.042 million | Loss increased 6.5% |
| Net loss | $16.813 million | $15.527 million | Loss increased 8.3% |
| Net loss per share | $1.81 | $2.38 | Improved due primarily to higher share count |
| R&D expense | $9.517 million | $9.303 million | +2.3% |
| Plasma center expense | $3.851 million | $2.418 million | +59.2% |
| General and administrative expense | $4.824 million | $4.365 million | +10.5% |
Operating expenses totaled $21.934 million, producing an operating margin of approximately negative 270.7%. The net margin was approximately negative 284.1%. Interest expense increased to $1.286 million from $0.618 million as debt outstanding increased. A $0.552 million state income-tax benefit resulted from the sale of New Jersey net operating losses and research credits.
Net cash used in operating activities was $14.705 million, compared with $10.887 million in 2013. Investing cash use was $4.041 million, including $2.323 million for property and equipment, primarily related to plasma-center expansion. Financing activities provided $9.795 million, primarily from Hercules debt financing.
At December 31, 2014, the company had $17.199 million of cash and cash equivalents, $4.653 million of short-term investments, and $19.9 million of working capital. Total debt-related liabilities included $14.772 million of notes payable, net of discount, plus a $0.477 million warrant liability. Total liabilities were $21.219 million, compared with stockholders’ equity of $6.009 million.
Material changes versus the prior comparable period
- Revenue increased substantially because of higher plasma collections and sales, supported by expanded donor hours, advertising, and additional collection equipment.
- Gross margin improved modestly, but higher plasma-center, R&D, administrative, and financing costs resulted in a larger net loss.
- R&D spending remained approximately $9.5 million as the Phase III RI-002 study was completed and regulatory preparation advanced.
- The company increased aggregate Hercules borrowings from $5.0 million at December 31, 2013 to $15.0 million at December 31, 2014.
- Cash and cash equivalents declined by $8.950 million, from $26.149 million to $17.199 million, despite the additional debt financing.
- ADMA expanded its Norcross plasma facility and opened a second Marietta, Georgia facility during the fourth quarter. Marietta remained pending FDA licensure and certification at year-end.
- ADMA listed its common stock on the NASDAQ Capital Market in November 2014.
Guidance, outlook, risks, contingencies, and unusual items
- Management expected to submit a Biologics License Application for RI-002 during the first half of 2015. Potential FDA approval was projected no earlier than the first half of 2016, but approval and timing were uncertain.
- Management expected cash, cash equivalents, and short-term investments to fund operations into the first half of 2016 based on projected 2015 revenue and expenses. The company had no committed additional financing arrangements and acknowledged that additional capital may be required sooner.
- Principal risks include failure to obtain FDA approval, limited clinical-trial size, reliance on one product candidate, dependence on third-party manufacturing and plasma suppliers, regulatory licensure of the Marietta facility, reimbursement uncertainty, and intense competition.
- Substantially all revenue was attributable to a single customer, Biotest, creating significant customer-concentration risk.
- The Hercules loan required principal and interest payments beginning October 1, 2015, matured no later than January 1, 2018, and was secured by company assets other than intellectual property. Specified defaults could accelerate repayment and permit seizure of collateral.
- The company’s contract manufacturer had received an FDA warning letter concerning an inspection at its Boca Raton location; ADMA stated that the warning had not affected RI-002 manufacturing or deliveries.
- ADMA had no issued patents and relied primarily on trade secrets, confidentiality agreements, proprietary assays, and two pending provisional patent applications.
- The company had cumulative losses of approximately $69.4 million since inception and expected continuing negative operating cash flow and losses.
- Future minimum lease payments for the Georgia plasma facilities totaled approximately $3.223 million. No material legal proceedings were pending at year-end.
Most important facts for an investor to verify
- Whether the RI-002 BLA was filed as planned and the status, timing, and substantive outcome of FDA review.
- Whether the Phase III results are accepted by the FDA and whether additional clinical, manufacturing, or post-approval studies are required.
- Actual cash burn, available liquidity, and the company’s ability to refinance or repay the Hercules debt beginning in October 2015.
- Whether the Marietta facility obtained FDA licensure and became operational at the expected collection capacity.
- The sustainability and terms of plasma sales to Biotest, including the effect of customer concentration and any minimum-purchase obligations.
- Whether RI-002 receives reimbursement and market acceptance if approved, and the potential impact of competing immune-globulin products.
- The company’s need for additional equity or debt financing and the resulting dilution or restrictions on operations.
- Changes in warrant, option, and share counts that could affect dilution and reported earnings volatility.